Is Cara Therapeutic Stock a Good Investment?
Cara Therapeutic Investment Advice | CARA |
- Examine Cara Therapeutic's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cara Therapeutic's leadership team and their track record. Good management can help Cara Therapeutic navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Cara Therapeutic's business and its evolving consumer preferences.
- Compare Cara Therapeutic's performance and market position to its competitors. Analyze how Cara Therapeutic is positioned in terms of product offerings, innovation, and market share.
- Check if Cara Therapeutic pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cara Therapeutic's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cara Therapeutic stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cara Therapeutic is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cara Therapeutic Stock
Researching Cara Therapeutic's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.75. Cara Therapeutic had not issued any dividends in recent years. The entity had 1:2 split on the 16th of January 2014.
To determine if Cara Therapeutic is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cara Therapeutic's research are outlined below:
| Cara Therapeutic generated a negative expected return over the last 90 days | |
| Cara Therapeutic has some characteristics of a very speculative penny stock | |
| Cara Therapeutic has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (56.14 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cara Therapeutic has a strong financial position based on the latest SEC filings | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Cara Q3 Earnings Snapshot |
Cara Therapeutic Quarterly Cash And Short Term Investments |
|
Cara Therapeutic uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cara Therapeutic. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cara Therapeutic's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cara Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cara Therapeutic's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-11-02 | 2017-09-30 | -0.34 | -0.38 | -0.04 | 11 | ||
2016-11-03 | 2016-09-30 | -0.47 | -0.42 | 0.05 | 10 | ||
2019-03-12 | 2018-12-31 | -0.58 | -0.52 | 0.06 | 10 | ||
2016-08-04 | 2016-06-30 | -0.42 | -0.48 | -0.06 | 14 | ||
2015-05-12 | 2015-03-31 | -0.27 | -0.21 | 0.06 | 22 | ||
2014-08-07 | 2014-06-30 | -0.22 | -0.16 | 0.06 | 27 | ||
2014-11-10 | 2014-09-30 | -0.22 | -0.29 | -0.07 | 31 | ||
2014-05-12 | 2014-03-31 | -0.15 | -0.22 | -0.07 | 46 |
Know Cara Therapeutic's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cara Therapeutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cara Therapeutic backward and forwards among themselves. Cara Therapeutic's institutional investor refers to the entity that pools money to purchase Cara Therapeutic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stifel Financial Corp | 2024-06-30 | 443.2 K | Y-intercept (hong Kong) Ltd | 2024-06-30 | 414.7 K | Goldman Sachs Group Inc | 2024-06-30 | 389.7 K | Jane Street Group Llc | 2024-06-30 | 376.5 K | Two Sigma Investments Llc | 2024-06-30 | 254.2 K | Fmr Inc | 2024-09-30 | 210.3 K | Susquehanna International Group, Llp | 2024-06-30 | 185.8 K | State Street Corp | 2024-06-30 | 180.8 K | Hrt Financial Llc | 2024-06-30 | 163.7 K | Vanguard Group Inc | 2024-06-30 | 2.3 M | Chescapmanager Llc | 2024-06-30 | 1.7 M |
Cara Therapeutic's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.74 M.Market Cap |
|
Cara Therapeutic's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.89) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (0.94) | (0.89) | |
| Return On Equity | (2.08) | (1.97) |
Determining Cara Therapeutic's profitability involves analyzing its financial statements and using various financial metrics to determine if Cara Therapeutic is a good buy. For example, gross profit margin measures Cara Therapeutic's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cara Therapeutic's profitability and make more informed investment decisions.
Please note, the presentation of Cara Therapeutic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cara Therapeutic's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cara Therapeutic's management manipulating its earnings.
Evaluate Cara Therapeutic's management efficiency
Cara Therapeutic has return on total asset (ROA) of (0.6343) % which means that it has lost $0.6343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8432) %, meaning that it created substantial loss on money invested by shareholders. Cara Therapeutic's management efficiency ratios could be used to measure how well Cara Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.89. The current year's Return On Capital Employed is expected to grow to -1.15. At present, Cara Therapeutic's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.6 M, whereas Non Current Assets Total are forecasted to decline to about 9.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.05 | 1.00 | |
| Tangible Book Value Per Share | 1.05 | 1.00 | |
| Enterprise Value Over EBITDA | (0.27) | (0.26) | |
| Price Book Value Ratio | 0.70 | 0.67 | |
| Enterprise Value Multiple | (0.27) | (0.26) | |
| Price Fair Value | 0.70 | 0.67 | |
| Enterprise Value | 31.6 M | 30 M |
The strategic initiatives led by Cara Therapeutic's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.681 |
Basic technical analysis of Cara Stock
As of the 23rd of November, Cara Therapeutic shows the Mean Deviation of 3.2, standard deviation of 4.45, and Risk Adjusted Performance of 9.0E-4. Cara Therapeutic technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cara Therapeutic's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cara Therapeutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cara Therapeutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cara Therapeutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cara Therapeutic's Outstanding Corporate Bonds
Cara Therapeutic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cara Therapeutic uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cara bonds can be classified according to their maturity, which is the date when Cara Therapeutic has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Cara Therapeutic's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cara Therapeutic's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 9.0E-4 | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 3.2 | |||
| Coefficient Of Variation | (10,423) | |||
| Standard Deviation | 4.45 | |||
| Variance | 19.83 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.75) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 19.35 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 7.41 | |||
| Skewness | 0.2896 | |||
| Kurtosis | 0.21 |
| Risk Adjusted Performance | 9.0E-4 | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 3.2 | |||
| Coefficient Of Variation | (10,423) | |||
| Standard Deviation | 4.45 | |||
| Variance | 19.83 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.75) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 19.35 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 7.41 | |||
| Skewness | 0.2896 | |||
| Kurtosis | 0.21 |
Consider Cara Therapeutic's intraday indicators
Cara Therapeutic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cara Therapeutic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cara Therapeutic time-series forecasting models is one of many Cara Therapeutic's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cara Therapeutic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cara Stock media impact
Far too much social signal, news, headlines, and media speculation about Cara Therapeutic that are available to investors today. That information is available publicly through Cara media outlets and privately through word of mouth or via Cara internal channels. However, regardless of the origin, that massive amount of Cara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cara Therapeutic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cara Therapeutic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cara Therapeutic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cara Therapeutic alpha.
Cara Therapeutic Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cara Therapeutic can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cara Therapeutic Corporate Management
| Joana Goncalves | Chief Medical Officer | Profile | |
| Beth Weinberg | VP QA | Profile | |
| Joana MD | Chief Officer | Profile | |
| Eric Vandal | Senior Commercial | Profile | |
| Frdrique Menzaghi | Chief RD | Profile | |
| Iris Francesconi | Chief Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cara Therapeutic's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.